ELICIO THERAPEUTICS, INC. ELTX 深 滬
等待開盤 07-18 09:30:00 美东时间
9.30
+0.250
+2.76%
華盛通- 最 高9.50
- 今 開9.18
- 成交量 4.73万股
- 最 低 9.18
- 昨 收 9.05
- 總市值 1.49亿
- 52周最高 9.99
- 市盈率 靜 --
- 換手率 0.30%
- 52周最低 3.70
- 委 比 66.67%
- 總股本 1599.70万
- 歷史最高 263.00
- 量 比 1.44
- 振 幅 3.54%
- 歷史最低 2.96
- 每 手 1
- 風險率 1.58%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多HC Wainwright & Co. Maintains Buy on Elicio Therapeutics, Raises Price Target to $13
HC Wainwright & Co. analyst Robert Burns maintains Elicio Therapeutics (NASDAQ:ELTX) with a Buy and raises the price target from $10 to $13.
07-17 18:34
Elicio Therapeutics To Host June 25 Virtual KOL Event At 2:00 PM ET Highlighting Urgent Need And Phase 2 Progress Of AMP-Powered ELI-002 Vaccine For mKRAS-Driven Pancreatic Cancer
Elicio Therapeutics, Inc. (NASDAQ:ELTX, "Elicio" or the "Company"))), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced that it will host a
06-17 20:09
Elicio Therapeutics to Host Virtual KOL Event on June 25, 2025 to Discuss AMP-Powered ELI-002 for the Treatment of KRAS mutation-driven Pancreatic Cancer
Elicio Therapeutics将于2025年6月25日举办一场关于mKRAS驱动胰腺导管腺癌（PDAC）治疗的虚拟关键意见领袖（KOL）活动。活动将邀请两名顶尖专家参与，并重点讨论Elicio公司的淋巴结靶向两亲聚合物（AMP）平台及其主导产品ELI-002。ELI-002是一种基于AMP技术的治疗性疫苗，目前处于针对mKRAS驱动PDAC的随机2期临床试验阶段。活动还预计将涵盖AMP平台的优势及其在克服免疫逃逸方面的潜力。
06-17 12:00
Elicio Therapeutics secures $10M in financing
Elicio Therapeutics (NASDAQ:ELTX) has entered a $10M senior secured promissory note with existing investor, GKCC. The proceeds from the Note Financing, together with Elicio’s current cash and equivale...
06-04 20:03
Elicio Therapeutics Secures $10 Million in Financing
Elicio Therapeutics与现有投资者GKCC达成1000万美元高级担保票据融资协议，支持运营至2026年第一季度，包括2025年第三季度的AMPLIFY-7P二期中期分析。融资包括12.5%利率、2028年到期、24个月只付息期及认股权证，以增强财务灵活性，推进PDAC和CRC中的ELI-002组合疗法开发，巩固其AMP免疫技术平台。
06-04 12:00
Elicio Therapeutics Q1 EPS $(0.87) Misses $(0.83) Estimate
Elicio Therapeutics (NASDAQ:ELTX) reported quarterly losses of $(0.87) per share which missed the analyst consensus estimate of $(0.83) by 4.82 percent. This is a 24.35 percent increase over losses of $(1.15) per share
05-14 04:28
Elicio Therapeutics Advances Cancer Immunotherapy Pipeline
Elicio Therapeutics, Inc ( ($ELTX) ) has released its Q4 earnings. Here is a br...
04-01 12:03
Elicio Therapeutics appoints Preetam Shah as CFO
Elicio Therapeutics (NASDAQ:ELTX) said it has appointed Preetam Shah as its chief financial officer and its chief strategy officer. Shah had served as the finance chief of Cidara Therapeutics prior t...
03-24 19:20
Elicio Therapeutics stock slides on $10M securities offering
Elicio Therapeutics (NASDAQ:ELTX) shares fell over 18% premarket as the biotechnology company announced an offering to raise around $10.0 million. The company entered into definitive securities purcha...
01-30 21:27
